Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials.

A borderline significant survival benefit was seen with G17DT compared to placebo (median survival 150 vs 83 days; Wilcoxon P =0.047), although there was a lower incidence of metastatic stage IV disease in the G17DT arm (73 vs 84%, respectively) ( Gilliam et al , 2004 ).

also in 11,409 other papers